Clinical Trials

IMMU-132 (Sacituzumab Govitecan)

Immunomedics is currently sponsoring an international Phase 3 clinical trial in patients with relapsed triple-negative breast cancer who have previously received two or more therapies for their metastatic disease.

Product Availability

“Does Immunomedics have a Compassionate Use Program for IMMU-132?”

Immunomedics does not have a Compassionate Use Program for IMMU-132 at this time; however, patients with refractory/relapsed triple-negative breast cancer may be eligible for enrollment in the large ASCENT clinical trial ( Identifier: NCT02574455). Subjects are currently being recruited at 177 locations in the United States and Europe.

For more information on this clinical trial, please visit